- Home
- ICLR vs RDY Comparison
ICLR vs RDY Comparison
Compare ICLR & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICLR
- RDY
- Stock Information
- Founded
- ICLR 1990
- RDY 1984
- Country
- ICLR Ireland
- RDY India
- Employees
- ICLR N/A
- RDY N/A
- Industry
- ICLR Biotechnology: Commercial Physical & Biological Resarch
- RDY Biotechnology: Pharmaceutical Preparations
- Sector
- ICLR Health Care
- RDY Health Care
- Exchange
- ICLR Nasdaq
- RDY Nasdaq
- Market Cap
- ICLR 14.3B
- RDY 11.6B
- IPO Year
- ICLR 1998
- RDY N/A
- Fundamental
- Price
- ICLR $178.10
- RDY $14.63
- Analyst Decision
- ICLR Buy
- RDY Strong Buy
- Analyst Count
- ICLR 15
- RDY 2
- Target Price
- ICLR $211.36
- RDY $16.95
- AVG Volume (30 Days)
- ICLR 1.0M
- RDY 1.0M
- Earning Date
- ICLR 10-22-2025
- RDY 10-24-2025
- Dividend Yield
- ICLR N/A
- RDY 0.49%
- EPS Growth
- ICLR N/A
- RDY 9.94
- EPS
- ICLR 7.47
- RDY 0.79
- Revenue
- ICLR $8,102,602,000.00
- RDY $3,851,623,984.00
- Revenue This Year
- ICLR N/A
- RDY $7.33
- Revenue Next Year
- ICLR $1.68
- RDY $2.00
- P/E Ratio
- ICLR $24.08
- RDY $18.44
- Revenue Growth
- ICLR N/A
- RDY 14.10
- 52 Week Low
- ICLR $125.10
- RDY $12.26
- 52 Week High
- ICLR $242.72
- RDY $16.17
- Technical
- Relative Strength Index (RSI)
- ICLR 45.22
- RDY 56.35
- Support Level
- ICLR $173.47
- RDY $14.58
- Resistance Level
- ICLR $198.30
- RDY $14.95
- Average True Range (ATR)
- ICLR 7.63
- RDY 0.22
- MACD
- ICLR -1.08
- RDY 0.06
- Stochastic Oscillator
- ICLR 18.63
- RDY 68.75
About ICLR ICON plc
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.
About RDY Dr. Reddy's Laboratories Ltd
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.